Our results provide evidence to contradict that sulfur vacancies indicate the origin of n-type behaviour in MoS2. This work provides a rational strategy for tuning the electronic structures of MoS2.Correction for 'A facile deoxyuridine/biotin-modified molecular beacon for simultaneous detection of proteins and nucleic acids via a label-free and background-eliminated fluorescence assay’ by Fei Yin, et al., Analyst, 2019, 144, 5504-5510, DOI 10.1039/C9AN01016E.Milk is a homogeneous mixture of substances such as lactose, proteins, and glycerides. Among carbohydrates, lactose is a disaccharide composed of glucose and galactose, and it is present in bovine milk at a level of 4.6%. According to resolution no. 135 of the National Health Surveillance Agency (ANVISA) from Brazil, dairy products labeled „lactose-free” must contain 1.0 mg mL-1 or less of this disaccharide. Thus, this work aims to develop and validate a method for quantifying the lactose content by quantitative nuclear magnetic resonance without the use of deuterated solvent (No-D qMNR). The validation of the developed method followed the norms provided by ANVISA resolution RDC no. 166, based on the figures of merit such as selectivity, linearity, the limit of detection (LOD) and quantification (LOQ), accuracy, precision, and robustness. The obtained results validated the method due to excellent linearity, demonstrated by the value of R > 0.990 and the homoscedasticity of the results, as well as precision, accuracy, and robustness values lower than 5%. Furthermore, LOD and LOQ values around 0.1345 mg mL-1 and 0.4076 mg mL-1, respectively, were obtained, which are lower than those required by legislation. The No-D qNMR technique was also able to quantify lactose content in commercial lactose-free milk.We use electron-beam patterned functional microgels to integrate self-reporting molecular beacons, dielectric microlenses, and solid-phase and/or solution-phase nucleic acid amplification in a viral-detection microarray model. The detection limits for different combinations of these elements range from 10-10 M for direct target-beacon hybridization alone to 10-18 M when all elements are integrated simultaneously.In this study, a method for the qualification and quantification of 4 psychoactive substances in tea using ultra high performance liquid chromatography coupled with the quadrupole time-of-flight mass spectrometry (UPLC-Q-TOF/MS) has been developed. Tea samples were extracted by a 50% (v/v) methanol-water solution, and then separated by an ACQUITY UPLC BEH Shield RP18 column using a binary solvent system by gradient elution. The analytes were determined by Q-TOF/MS in TOFMS and information-dependent acquisition (IDA)-MS/MS mode. The results showed that the mass accuracy error of the 4 psychoactive substances were lower than 5.0 × 10-6, and a good linear relationship was observed in the range of 0.5-500 μg L-1 and correlation coefficient was higher than 0.9990. The LOD was in the range of 0.005-0.020 mg kg-1 and the LOQ was in the range of 0.010-0.040 mg kg-1. The recovery of the method was in range of 80.14-93.25% with spike levels of 0.010-0.400 mg kg-1, and relative standard deviations were lower than 10%. The method was simple, specific and reliable. It has been successfully used for the detection of 4 psychoactive substances in tea samples.Secondary structures in long circulating tumor nucleic acids have potential obstacles for specific location point hybridized detection of gene fragments. The exploration of biosensing strategies requires selectively changing the nucleic acids conformation and inducing signal switching. Herein, a self-assembled magnetic composite probe (MCP) was fabricated by the hybridization reaction of Linker DNA and a „Y”-junction-DNA nanostructure on the surface of magnetic beads, contributing to the capture, secondary structure unlocking, and enrichment of the PML/RARα DNA „L” subtype. Then, by integrating the MCP-actuated reactor, a one-step „off-on” signal switching MoS2@FAM-probe biosensing method was developed for the efficient detection of the PML/RARα DNA „L” subtype. The proposed biosensor was capable of detecting 100 bases PML/RARα DNA „L” subtype with a wide linear range of 1 pM to 200 nM and a limit of detection down to 0.223 pM without signal amplification. In addition, the biosensing method was successfully applied for the detection of target in serum samples. It is worth pointing out that this simple biosensing strategy could enable long nucleic acids fragments with secondary structures from ctDNA and ctRNA to be quantitatively assayed based on direct hybridization.We describe a microfabricated passive preconcentrator (μPP) intended for integration into gas chromatographic microsystems (μGC) for analyzing volatile/semi-volatile organic compounds (S/VOC). Devices (8 × 8 mm) were made from a silicon-on-insulator top layer and a glass bottom layer. The top layer has 237 apertures (47 × 47 μm) distributed around the periphery of a circular region (5.2 mm o.d.) through which ambient vapors diffuse at predictable rates. Two internal annular cavities offset from the apertures are packed with ∼800 μg each of commercial carbon adsorbents. Thin-film heaters thermally desorb captured vapors, which are drawn by a pump through a central exit port to a micro injector for analysis with a bench scale GC. The 15 test compounds spanned a vapor pressure range of 0.033 to 1.1 kPa. Effective (diffusional) μPP sampling rates ranged from 0.16 to 0.78 mL min-1 for short-duration exposures to ∼mg m-3 vapor concentrations. Observed and modeled sampling rates generally agreed within 15%. Sampling rates for two representative compounds declined by ≤30% between 0.25 and 24 h of continuous exposure. For one of these, the sampling rate declined by only 8% over a ∼2300-fold concentration range (0.25 h samples). Desorption (transfer) efficiencies were >95% for most compounds (250-275 °C, 60 s, 5 mL min-1). Sampling rates for mixtures matched those for the individual compounds. Dissipating no energy while sampling, additional advantages of this novel device include short- or long-term sampling, high capacity and transfer efficiency for a diverse set of S/VOCs, low transfer flow rate, and a robust fabrication process.Synchrotron-based X-ray absorption spectroscopy and scattering are known in situ probes of metal nanoparticles (NPs). A limited number of laboratory techniques allow post-synthesis diagnostics of the active metal surface area. This work demonstrates the high potential of infrared spectroscopy as an in situ laboratory probe for the growth of metal NPs on a substrate. We introduce a small fraction of CO molecules into the reaction mixture as a probe to monitor the reduction kinetics of the Pd2+ precursor on ceria in hydrogen.The unprecedented development of prostate cancer therapy is a challenge for the proper sequential use of modern medicines. Patients’ life expectancies improve when we use treatment lines, one after the other. There is no evidence- based guideline regarding the optimal sequence, but a number of data are available to help the physician selecting the best individualized therapeutic option. The basic treatment for advanced prostate cancer is still androgenic deprivation (ADT), to which we can add additional therapeutic agents. New types of hormonal (androgen receptor targeted, ARTA) agents are being used in an increasingly early line. Chemotherapy (CT) is the first choice in case of metastatic, hormone-sensitive disease especially in high volume cases that are causing symptoms or visceral crisis. CT is otherwise applied after ARTA. We have little but encouraging data about the early, sequential use of ARTAs with different mechanisms of action. In later lines, cross-resistance may develop between ARTA treatments, in which cases CT is the right decision. In this paper, we summarize the results of clinical trials that may help in therapeutic decision making, maximizing the benefits for patients.Lung cancer is known for its outstanding incidence and mortality rates. One of the cornerstones of the treatment of this disease is radiation therapy. A remarkable development was observed in this field through the latest decades. Intensity-modulated and image-guided radiotherapy (IMRT and IGRT) are now widely accessible in Hungarian centers, and should be increasingly applied in case of thoracic irradiations as well. Application of modern radiotherapy techniques in the treatment of lung cancer allows better clinical results and lower rates of side effects. In this work the authors give an overview of this above mentioned development regarding different clinical stages.Over the past 15 years, it has become evident that molecular genetic testing has a place in the management of lung cancer patients in routine clinical practice. Initial monogenic examinations are increasingly being replaced by genomic investigations that analyze multiple genes, or even hundreds of genes. In the present paper, the author briefly summarizes the main therapeutic targets for genomic study of non-small cell and small cell lung cancers. In addition, two exciting areas of genomic research through the results of international research with domestic participation are also presented gene expression pattern analysis predicting lung cancer prognosis, and study on tumor evolution and genetic effect of oncotherapies.Immune checkpoint inhibitor therapy in lung cancer is a new effective treatment as part of a complex treatment strategy. In the advanced stage of non-small cell non-squamous lung cancer, without actionable mutation, the immune monotherapy or combination treatment with platinum based chemotherapy is a new standard of care depending on PD-L1 status. In case of advanced squamous cell lung cancer the situation is similar. The exact role of combination PD-1 axis and CTLA-4 inhibitor treatment with or without chemotherapy is not exactly defined. Immune checkpoint inhibitor therapy can be used in second or more line treatment as well. After exhaustion of targeted treatment the efficacy of the combination of immunotherapy with angiogenesis inhibitor and platinum based chemotherapy is promising. In locally advanced non-small cell lung cancer after radiochemotherapy the consolidation PD-L1 inhibitor treatment is a new standard of care in case of PD-L1 positivity. There are Phase III trials in neoadjuvant and adjuvant setting as well. In extensive stage small cell lung cancer the platinum-etoposide treatment with PD-L1 inhibitor is a new standard, but we do not have any effective biomarkers yet.More than 6 million mutations of more than 600 cancer genes can occur in over 200 tumor types according to the COSMIC (Catalogue of Somatic Mutations in Cancer) database. The theoretical combination of all „driver” alterations and tumor types adds up to an enormous number. Therefore, there is a legitimate need to use the same targeted therapy in the presence of its target and mechanism of action in multiple tumor types. The first tissue-agnostic drugs that are registered solely based on molecular biomarkers are the NTRK inhibitors (larotrectinib and entrectinib) and the PD-1 inhibitor pembrolizumab in microsatellite instable (MSI) and tumor mutation burden (TMB) high tumors. These targets are also present in lung cancer, and we have clinical proof of the activity of treatments. In addition, the molecular targets of many targeted therapies registered in other tumor types occur in lung cancer for target-based tissue-agnostic therapy planning in lung cancer.